Persistence and risk factors of high-risk human papillomavirus infection among HIV positive and HIV negative tanzanian women: a cohort study.
HIV status
HR HPV
Persistence
Risk factors
Tanzania
Journal
Infectious agents and cancer
ISSN: 1750-9378
Titre abrégé: Infect Agent Cancer
Pays: England
ID NLM: 101276559
Informations de publication
Date de publication:
11 Jun 2022
11 Jun 2022
Historique:
received:
13
03
2022
accepted:
30
05
2022
entrez:
11
6
2022
pubmed:
12
6
2022
medline:
12
6
2022
Statut:
epublish
Résumé
High-risk (HR) human papillomavirus (HPV) persistence is the most important risk factor for cervical cancer. We have assessed the type-specific HR HPV persistence among HIV positive and HIV negative Tanzanian women and factors associated with HR HPV persistence. In a cohort study including 4080 Tanzanian women, 3074 attended follow-up examination (up to 32 months after enrollment). Cervical samples were obtained for liquid-based cytology and HPV DNA testing using Hybrid Capture 2 and Inno-Lipa Extra II. Information on lifestyle factors was collected through a personal interview. The probability of HR HPV persistence at a given time point since enrollment was estimated non-parametrically using the EMICM algorithm. Among the 462 women HR HPV positive at enrollment, 158 had at least one identical type detected at follow-up. The probability of persistence at 18 months after enrollment was 34.2 (95% CI 29.0-39.4). Stratifying by HIV status, the persistence probability was 42.9% (95% CI 33.5-51.9) among HIV positive, and 28.0% (95% CI 22.1-34.2) among HIV negative. Overall, HR HPV persistence was most common for HPV58, 35, 16, 31, and 52. Among HIV positive women it was HPV45, and HPV16, followed by HPV58 and HPV18, and among HIV negative women it was HPV31, HPV33 and HPV58. Risk factors associated with persistence of HR HPV were older age, longer interval between enrollment and follow-up, binge drinking, and HIV status. HR HPV persistence was common in Tanzania, and most common among HIV positive women. Overall, persistence was most frequent for HPV 58, 35, 16, 31 and 52. The nonavalent HPV vaccine should be considered.
Sections du résumé
BACKGROUND
BACKGROUND
High-risk (HR) human papillomavirus (HPV) persistence is the most important risk factor for cervical cancer. We have assessed the type-specific HR HPV persistence among HIV positive and HIV negative Tanzanian women and factors associated with HR HPV persistence.
METHODS
METHODS
In a cohort study including 4080 Tanzanian women, 3074 attended follow-up examination (up to 32 months after enrollment). Cervical samples were obtained for liquid-based cytology and HPV DNA testing using Hybrid Capture 2 and Inno-Lipa Extra II. Information on lifestyle factors was collected through a personal interview. The probability of HR HPV persistence at a given time point since enrollment was estimated non-parametrically using the EMICM algorithm.
RESULTS
RESULTS
Among the 462 women HR HPV positive at enrollment, 158 had at least one identical type detected at follow-up. The probability of persistence at 18 months after enrollment was 34.2 (95% CI 29.0-39.4). Stratifying by HIV status, the persistence probability was 42.9% (95% CI 33.5-51.9) among HIV positive, and 28.0% (95% CI 22.1-34.2) among HIV negative. Overall, HR HPV persistence was most common for HPV58, 35, 16, 31, and 52. Among HIV positive women it was HPV45, and HPV16, followed by HPV58 and HPV18, and among HIV negative women it was HPV31, HPV33 and HPV58. Risk factors associated with persistence of HR HPV were older age, longer interval between enrollment and follow-up, binge drinking, and HIV status.
CONCLUSIONS
CONCLUSIONS
HR HPV persistence was common in Tanzania, and most common among HIV positive women. Overall, persistence was most frequent for HPV 58, 35, 16, 31 and 52. The nonavalent HPV vaccine should be considered.
Identifiants
pubmed: 35690838
doi: 10.1186/s13027-022-00442-2
pii: 10.1186/s13027-022-00442-2
pmc: PMC9188099
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
26Informations de copyright
© 2022. The Author(s).
Références
BMC Infect Dis. 2011 Dec 02;11:333
pubmed: 22136570
Infect Agent Cancer. 2021 Feb 19;16(1):16
pubmed: 33608036
Vaccine. 2018 Aug 6;36(32 Pt A):4761-4767
pubmed: 29580641
Cancer Epidemiol Biomarkers Prev. 2010 Dec;19(12):3044-54
pubmed: 20952561
Sex Transm Dis. 2019 Aug;46(8):532-539
pubmed: 31295222
Front Public Health. 2017 Jul 21;5:178
pubmed: 28785554
Epidemiol Infect. 2015 May;143(7):1442-50
pubmed: 25185457
Vaccine. 2013 Nov 22;31 Suppl 8:I1-31
pubmed: 24229716
Health Policy Plan. 2020 Jul 1;35(6):701-717
pubmed: 32538437
Vaccine. 2017 Dec 14;35(49 Pt B):6823-6827
pubmed: 29122384
AIDS. 2006 Nov 28;20(18):2337-44
pubmed: 17117020
Int J Infect Dis. 2015 Apr;33:219-21
pubmed: 25697074
JNCI Cancer Spectr. 2019 Jan 07;2(4):pky045
pubmed: 31360870
AIDS. 2017 Jan 14;31(2):273-285
pubmed: 27755107
EClinicalMedicine. 2020 Apr 25;22:100293
pubmed: 32510043
J Infect Dis. 2008 May 15;197(10):1436-47
pubmed: 18419547
J Natl Cancer Inst Monogr. 2003;(31):35-40
pubmed: 12807943
HIV Med. 2019 Aug;20(7):485-495
pubmed: 31318136
Am J Pathol. 1999 Nov;155(5):1473-8
pubmed: 10550303
J Infect Dis. 2007 Jun 1;195(11):1582-9
pubmed: 17471427
Br J Cancer. 2009 Apr 7;100(7):1184-90
pubmed: 19293802
BMJ Open. 2020 Sep 18;10(9):e038531
pubmed: 32948569
Lancet Glob Health. 2020 Feb;8(2):e180-e190
pubmed: 31862245
Vaccine. 2006 Aug 31;24 Suppl 3:S3/42-51
pubmed: 16950017
J Med Virol. 2010 Apr;82(4):616-23
pubmed: 20166190
BMC Womens Health. 2020 Mar 31;20(1):65
pubmed: 32234028